Used in the treatment of glioblastoma, a type of brain cancer, GDC-0084 is designed to inhibit specific signaling pathways involved in tumor growth and survival. It crosses the blood-brain barrier effectively, making it suitable for targeting central nervous system tumors. The compound primarily acts as an inhibitor of PI3K and mTOR pathways, which are often dysregulated in cancer cells. This dual inhibition helps suppress cancer cell proliferation and promote cell death. It has been evaluated in clinical trials for its efficacy and safety in patients with recurrent glioblastoma, showing potential to improve progression-free survival. Its development represents a targeted therapy approach in neuro-oncology.